Investors & Media Home

Mesoblast is a world leader in cell-based medicines.

The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late-stage product candidates.

These allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, orthopedic disorders, oncology and... More

Latest ASX AnnouncementsMore
25 August 2016
Mesoblast Reports on Annual and Fourth Quarter Results
... 
25 August 2016
Annual Financial Results Presentation
... 
25 August 2016
Preliminary Final Report (Including Appendix 4E)
... 
19 August 2016
Appendix 3B
... 
Latest Press ReleasesMore
24 February 2016
First Allogeneic Cell Therapy Product Launched in Japan by Mesoblast Licensee
NEW YORK and MELBOURNE, Australia, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MES... 
22 February 2016
Increased Survival Using MSB Cells In Children With aGVHD
... 
17 February 2016
Mesoblast Reports on First Half and Second Quarter Financial Results
MELBOURNE, Australia and NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (... 
16 February 2016
MSB Therapy Shows Benefit In First Cohort Of RA Patients
... 
Upcoming EventsMore
There are currently no events scheduled.
Stock QuoteMore
Exchange :ASX
Price :A$1.38
Change :0.00 (0.00%)
Volume :0
Data as of 26 August 2016 7:01 a.m. ET
Data provided by Nasdaq Minimum 15 minutes delay
Download Documentation 2016 Full Year Results
Download Documentation Third Quarter 2016 Financial Results
Download Documentation Second Quarter 2016 Financial Results
E-mail Alerts
Sign up to receive e-mail alerts.

Share Price ASX: MSB  AUD 1.38 as of Aug 26, 2016